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Abstract - The utility of EEG in Alzheimer’s disease (AD) 
research has been demonstrated over several decades in numerous 
studies. EEG markers have been employed successfully to 
investigate AD-related alterations in prodromal AD and AD 
dementia. Preclinical AD is a recent concept and a novel target for 
clinical research. This project tackles two issues: first, AD 
prediction at the preclinical stage, by exploiting the multimodal 
INSIGHT-preAD database, acquired at the Pitié-Salpetrière 
Hospital; second, an automatic AD diagnosis in a differential 
framework, by exploiting another large-scale EEG database, 
acquired at Charles-Foix Hospital. In this project, we will 
investigate AD predictors at preclinical stage, using EEG data of 
only subjective Memory Complainers in order to establish a 
cognitive profiling of elderly at-risk. We will also identify EEG 
markers for AD detection at early stages in a differential diagnosis 
context. The correlation between EEG markers and clinical 
biomarkers will be also assessed for a better characterization of the 
retrieved profiles and a better understanding on the severity of the 
cognitive disorder. The exploited large-scale complementary data 
offer the opportunity to investigate the full spectrum of the AD 
neuro-degeneration changes in the brain, using a big data approach 
and multimodal patient profiling based on resting-state EEG 
markers. 
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I. INTRODUCTION 
Alzheimer’s disease (AD) is a chronic neurodegenerative 
disorder that leads to progressive decline of cognitive functions, 
along with behavioral disturbances and insidious loss of 
autonomy in daily life activities. Its incidence increases 
exponentially with age, and doubles every 5 years after the age 
of 65 [1-3], being the most common cause of dementia in 
Western societies. As the world population ages, the frequency 
is expected to double by 2030 and triple by 2050 [4]. 
Accordingly, and because of the unprecedented level of aging 
in the world, the health care costs associated with AD are 
exceptionally high, imposing an important burden on modern 
societies.  
 The evolution of AD follows five stages. The “preclinical” 
stage is asymptomatic, but the brain lesions of AD are present. 
At this stage, the concept of Subjective Cognitive Impairment 
(SCI) has been proposed recently, defined by a self-experienced 
persistent decline in cognitive capacity in comparison with a 
previously normal status [5]. These subjective complaints are 
considered as a risk factor for AD [6,7]. Then, in “Mild 
Neurocognitive Disorders” (MND) stage, patients exhibit 
measurable memory impairments, but maintain their functional 
capacities [7,8]. In the “Mild AD” stage, cognitive deficits are 
more notable, such as memory and learning impairments. These 
syndromes become more severe in the “Moderate AD” stage 
and in the final “severe” stage of the disease, almost all 
cognitive and motor functions are significantly deteriorated and 
patients lose autonomy becoming completely dependent on 
caregivers. The average duration of survival of AD patients is 
5-8 years after clinical diagnosis [9]. 
    In the initial stages of the disease, AD targets limbic regions 
that subserve episodic memory, leading to a relatively 
circumscribed inability to learn and retain new information. 
Also, a disruption of fronto-hippocampal connections has been 
found to occur from the early stages of AD, in parallel with 
hippocampal atrophy, and it has been reported that it may 
specifically contribute to the initial memory impairment in AD 
patients [10]. Over time, AD spreads to other neocortical 
regions [11], affecting additional spheres of cognition, such as 
executive functions, attention, visuospatial abilities and 
language. Characteristic neuropathological findings include 
selective neuronal and synaptic losses [12], extracellular 
neuritic plaques containing the b-amyloid peptide [13] and 
neurofibrillary tangles composed of hyperphosphorylated forms 
of the tau protein [14].  
    No medication exists to stop or reverse the disease 
progression, and many therapeutics trials failed and their cost-
effectiveness has been questioned [15,16]. Current major anti-
AD medication trials are focusing on “preclinical” stage, in 
order to treat before symptoms development. Therefore, AD 
detection at MND and preclinical stages becomes an important 
issue for the scientific community.  
    Besides, there are currently no specific markers that can 
confirm the AD diagnosis with sufficient certainty, especially 
in the early stages. Thus, there is a crucial need for real 
advances to identify reliable AD markers for profiling elderly 
at-risk, diagnosis and monitoring disease progression.  
    New approaches to these complex challenges require a mix 
of resources and skill sets from different disciplines to enhance 
and forward AD research. This is the objective of our 
collaborative research work that we present in this paper. The 
project started in December 2018 and involves three French 
partners: two hospitals from AP-HP in France, Salpêtrière 
Hospital and Charles-Foix Hospital, and Samovar Laboratory of 
Télécom SudParis. 
    This paper offers an insight on current transdisciplinary 
research, including data analytics computing and clinical data 
fusion, for prognosis, diagnosis, and monitoring the evolution 
of AD. By relying on signal processing, data analytics and 
machine learning techniques, we target to identify neuro-
imaging- and new neuro-dynamic biomarkers correlated with 
AD, which contribute to a better understanding of the brain 
dynamics of AD patients, and improve the prediction of elderly 
at-risk and the reliability of AD diagnosis.  
    This research project concerns the multi-dimensional 
profiling of elderly at-risk for AD in a differential framework, 
and exploits two complementary large-scale EEG databases, 
acquired at Salpêtrière and Charles-Foix Hospitals. Télécom 
SudParis team is in charge of processing and analyzing these 
two databases by applying signal processing methods, statistical 
and machine learning techniques. Such analyses will be based 
on the clinical expertise of the medical staff. 
 
 
II. STATE OF THE ART 
The prognostic utility of electroencephalography (EEG) in 
Alzheimer’s disease (AD) research has been demonstrated over 
several decades in numerous studies [17-27].  
    EEG is a non-invasive, relatively inexpensive, and potentially 
mobile technology with high temporal resolution (on the order 
of milliseconds). It was mainly investigated as a tool for AD 
diagnosis, by comparing EEG recordings of AD patients only to 
those of control subjects (healthy subjects) [28-33]. 
    The measurable electrophysiological changes may be due to 
loss of gray matter and, more importantly, loss of neuronal 
connections [34]. EEG biomarkers have been employed 
successfully to investigate AD-related alterations in the brain 
dynamics with two main approaches - using spontaneous 
resting-state EEG (rsEEG) and functional EEG (fEEG) based 
on event-related responses (ERP). Several brainwave 
components of the rsEEG could be altered in various stages of 
AD.  
    Evidence from a number of studies indicates that AD leads to 
a reduction in the complexity of EEG signals and changes in 
EEG synchrony, in prodromal AD and AD dementia. These 
modifications in EEG recordings have been used as 
discriminative features for AD diagnosis. Several methods were 
developed for assessing the complexity of EEG signals. The 
correlation dimension and the first positive Lyapunov exponent 
were frequently used [20, 35-39]. It was found that EEG signals 
from AD patients exhibit lower values of such measures than 
signals from healthy subjects. Other information-theoretic 
methods, entropy-based approaches in particular, have emerged 
as potentially useful EEG markers of AD [21-23,25,26]: epoch-
based entropy [21-23], sample entropy [24], Tsallis entropy 
[25], approximate entropy [40,41], multi-scale entropy [26], and 
Lempel-Ziv complexity [42].  
    Since AD is hypothesized to induce functional disconnection 
between brain regions, other works focused on synchrony 
changes detection [19-22] between pairs of EEG signals. A 
large variety of measures has been developed to quantify EEG 
synchrony: correlation coefficient [27], coherence [27,43,44], 
Granger causality [27,45], phase synchrony [27,46,47], state 
space-based synchrony [27,46,48], stochastic event synchrony 
[27,44,47,49,50] and mutual information [51]. All these studies 
reported decreased EEG synchrony in MND and AD patients 
compared to healthy subjects. 
    To discriminate AD patients from healthy subjects, all the 
above-mentioned studies analyzed the EEG signals either in the 
time domain or in specific standard frequency bands: 0.1–4Hz 
(delta band), 4–8Hz (theta band), 8–12Hz (alpha band), 12–
30Hz (beta band) and 30–100Hz (gamma band) [39,52] or in 
the whole frequency range between 4 and 30Hz [27]. 
    Spectral analysis studies reported that, in prodromal AD and 
AD dementia, there is an enhancement of low-frequency waves 
in the theta [53] and delta bands in the temporal and occipital 
lobes, as well as a reduction of higher-frequency beta power in 
the temporal and occipital regions [54-56] and a decline in 
alpha band (8–12 Hz) power [30,57-59]. A reduced spectral 
coherence between the two hemispheres was also shown 
between alpha and beta frequency bands [60-62]. These spectral 
differences were also shown to be correlated with the severity 
of the disease [60,63,64]. Moreover, alpha rhythms are usually 
distributed in the occipital area for healthy subjects; in AD 
patients, they increasingly move towards anterior areas as the 
disease progresses [58,65,66]. Early stages of AD have been 
associated with an increase of theta activity and/or a decrease of 
alpha activity. In more severe stages of Alzheimer's disease, an 
increase of both theta and delta activities has been observed 
together with a decrease of both alpha and beta activities, 
additionally to a reduction in the amplitude of the peak of alpha 
frequency band [67,68]. In all these studies, a 70%-85% correct 
detection rate is commonly achieved for different degrees of 
disease severity.  
    All the above-mentioned investigations have some 
limitations: 
(i) First, most works report studies conducted on small 
databases, of around 20 persons, containing EEG 
signals from only healthy subjects and AD patients (a 
2-class classification problem); 
(ii) Second, the proposed methods in the literature tend to 
have a low specificity, hence poor detection of 
healthy subjects; 
(iii) Third, for all these studies, the accuracy of AD 
diagnosis is not evaluated in a differential diagnosis 
context with respect to other pathologies; 
(iv) Fourth, at-risk- or preclinical AD individuals have not 
been studied systematically due to the previous lack 
of clear group definitions, and challenges with subtle 
differences to age-matched healthy controls. 
 
III. MAIN GOALS OF THE PROJECT, EXPECTED INNOVATIONS 
This collaborative research work differs completely from the 
works reported in the literature on AD detection. By contrast, 
this project:  
- First, addresses the problem of AD prognosis/prediction 
at the “preclinical stage” based on the fusion of EEG 
markers and available clinical data. It differs from 
previous studies in the scientific literature both due to its 
study population (preclinical AD) and the data analysis 
techniques, based on the statistical modeling of the 
multidimensional EEG signal and multimodal data fusion. 
Previously, EEG has been used mainly as a tool for AD 
diagnosis, as widely demonstrated by comparing EEG 
signals of AD dementia patients to those of healthy 
subjects (a classification problem). In contrast, this 
project investigates early AD predictors at the preclinical 
stage, using complex EEG data indicators in amyloid-
positive and amyloid-negative subjective memory 
complainers (a clustering problem). Our aim is twofold:  
(i) to establish automatically a profiling of elderly at-risk 
of AD;  
(ii) to identify the markers of progression to clinical AD 
in asymptomatic at-risk individuals.  
- Second, it investigates EEG markers for an early 
automatic AD detection at MND and Mild AD stages in a 
differential diagnosis context. To our knowledge, 
automatic discrimination from EEG data between SCI, 
MND, and Mild AD patients was not addressed in the 
literature. A similar work in the literature in terms of the 
exploited cohort is that of Liedorp et al. [69], on which 
abnormalities in different cognitive profiles were 
investigated based on a visual EEG assessment.  Our aim 
in this project is twofold:  
(v) to discriminate automatically possible AD patients 
from patients who came to the hospital with cognitive 
complaint but with normal age-, gender -and 
education-adjusted performance on cognitive tests i.e. 
SCI patients (AD diagnosis); 
(vi) to discriminate automatically possible AD patients 
from SCI patients and patients with MND or other 
pathologies (differential AD diagnosis). 
- Third, it investigates the progression towards dementia by 
analyzing the evolution of EEG markers, in a transversal 
way, from SCI, MND to Mild AD, and also in a 
longitudinal way. 
- Fourth, it assesses the correlation between EEG markers 
and clinical biomarkers for a better characterization of the 
cognitive profiles and a better understanding on the 
severity of the cognitive disorder and the AD diagnosis. 
 
    This project takes advantage of two large-scale EEG 
databases, acquired at two clinical centers of AP-HP: The 
multimodal INSIGHT-preAD database and the Charles-Foix 
database. 
 
IV. DESCRIPTION OF THE TWO CLINICAL EEG DATABASES  
These two unique large-scale complementary databases offer 
the opportunity to investigate the full spectrum of the AD 
neuro-degeneration changes in the brain, using a big-data 
approach and multimodal patient profiling with a major role 
for resting-state EEG markers.  
 
A. The multimodal INSIGHT-preAD database 
 
INSIGHT-preAD (INveStIGation of AlzHeimer’s PredicTors in 
Subjective Memory Complainers) is an on going and mono-
centric cohort study from the Salpêtrière Hospital, Paris, 
France, which started in 2013 [70]. The cohort includes 
cognitively normal individuals, over 70 years, with subjective 
memory complaints (SMC) but normal cognitive and memory 
scores according to the Mini Mental State Examination (MMSE 
≥ 27), Clinical Dementia Rating (CDR = 0) and Free and Cued 
Selective Reminding Test (Total Recall ≥ 41).  
    Subjects were stratified by brain amyloid status (amyloid 
positive or amyloid negative) according to the uptake of 18F-
Florbetapir. Demographic, cognitive, psycho-behavioral, 
functional, ApoE status, MRI (anatomical, diffusion, resting 
state-fMRI, arterial spin labeling sequences), FDG-PET 
imaging, EEG recordings with resting state and ERP, were 
performed at baseline with optional Actigraphy and CSF 
investigations.  
    All subjects participated in follow-up with 
neuropsychological assessment, EEG, and Actigraphy every 
year; blood samplings for research on biomarkers, MRI, FDG-
PET and amyloid-PET scans every 2 years. The clinical staff 
investigated the association between amyloid status and the 
assessed measures at baseline and month 24, and assessed the 
clinical status of participants at month 30 to identify the factors 
associated with progression to prodromal AD. 
    At baseline, the database contains EEG data of 318 elderly 
Subjective Memory Complainers, which had a mean age of 
76.03 (SD 3.47) years with a mean MMSE score of 28.67 (SD 
0.96) and a high educational level (6.19 [SD 2.05] on a scale of 
1-8).  
    EEG data were recorded using a high-density 256 channel 
EGI system (Electrical Geodesics Inc., USA) with a sampling 
rate of 250 Hz. The electrodes used are sponge-based in order to 
have a quick application time (10–20 min) due to the elderly 
population. During the recording, patients were instructed to 
keep awake and relaxed, with their eyes closed in a quiet room. 
60 s of eyes-closed resting-state were selected for analysis. 
    Due to the availability of resting-state EEG (rsEEG) and 
other multimodal information, such as amyloid-PET SUVr 
measures and an extensive battery of neuropsychological tests, 
it is possible to analyze the neuro-dynamics profiles of 
individuals at-risk for AD or in the preclinical AD stage by 
using different advanced signal analysis methods.  
 
B. The Charles-Foix database 
 
This database was recorded in real clinical conditions between 
2009 and 2013 at Charles-Foix Hospital (Ivry-sur-Seine, 
France). The EEG recordings were obtained at rest and with 
closed eyes using a Deltamed digital EEG acquisition system 
for a minimum of 20 minutes.  
    Scalp electrodes were placed according to the modified 
International 10-20 system with 11 additional electrodes in a 
common reference montage using a sampling rate of 256 Hz. 
Thirty electrodes were placed on the scalp: Fp1, Fp2, F7, F3, 
Fz, F4, F8, FT7, FC3, FC7, FC4, FT8, T3, C3, Cz, C4, T4, TP7, 
CP3, CPz, CP4, TP8, T5, P3, Pz, P4, T6, O1, Oz, O2. 
   The patients who complained of memory impairment were 
referred to the outpatient memory clinic of the Charles-Foix 
Hospital where they underwent a battery of tests for brain 
disorders, including neuropsychological test, brain imaging and 
blood samplings. Patients with epilepsy were excluded. Each 
patient was given a diagnosis at the memory clinic on the basis 
of the clinical, brain imaging, psychometric findings, and 
discussions held by a multidisciplinary medical team, using the 
standard diagnostic criteria:  DSM-IV, NINDS, Jessen criteria 
for SCI, Mc Keith criteria for Lewy body dementia [5,6]. We 
didn’t use EEG recordings to establish the diagnosis. 
    In this project we will pursue our previous small-scale study 
[21] on a part of this database. Indeed, in [21], we used EEG 
data of 169 patients (mean age 75±11.2 years old, range 42-97 
years old; 110 women): 22 SCI subjects, 58 MND patients, 28 
AD patients (DSM IV definition), 21 patients AD “mixed”, and 
40 patients suffering from other pathologies such as vascular 
dementia, psychosis, Lewy body dementia, and non 
neurodegenerative disorders (cerebral vascularitis, 
alcoholism…). 
    In this project, we will extend our study on new EEG data 
collected at Charles-Foix Hospital from 2013, as the first data 
collected between 2009 and 2013 were analyzed in our previous 
study [21]. 
    The database reflects what medical practitioners are facing in 
reality, as opposed to databases used in the literature 
[20,22,23,27,39,43-47] that are prone to experimental 
constraints that do not match the reality on the ground.  
     
V. SCIENTIFIC CONTENT 
The main research approaches for this project will be rsEEG 
feature extraction with signal processing techniques, 
unsupervised clustering methods to retrieve automatically 
cognitive profiles, data fusion, and supervised clustering 
techniques for AD diagnosis in a differential framework.  
    As mentioned in Section II, several EEG markers were 
developed in the literature for AD detection. These markers will 
be transposed to the framework of this project and applied as 
biomarkers for profiling elderly at-risk for AD in a differential 
framework. At each step of our experiments, several EEG 
markers will be evaluated, as well as available clinical data. 
Their fusion will be also investigated to characterize AD and 
elderly at-risk of AD. 
    This research project is organized in two parts: (i) AD 
prognostic (prediction) at the preclinical stage using the 
multimodal INSIGHT-preAD database; (ii) AD diagnosis in a 
differential framework, using the Charles-Foix database. 
Experimentally, our findings on Charles-Foix database will be 
exploited to address the issues tackled by INSIGHT-preAD 
database. 
 
A. INSIGHT-PreAD study: AD prognostic / prediction at the 
preclinical stage  
 
Preclinical AD is a relatively recent concept and a novel target 
for clinical research, especially in the field of EEG. Due to the 
availability of rsEEG and other multimodal information in the 
INSIGHT-preAD study, it is possible to study in detail the 
neurodynamics profiles of individuals at risk for AD or in the 
preclinical AD stage by using different advanced signal analysis 
methods.  
    This study was recently approved by the scientific committee 
of the Salpêtrière hospital. In this project, we aim to implement 
and investigate this concept using large-scale rsEEG feature 
extraction and fusion, in order to minimize the effects of inter-
subject variability and subjective signal feature pre-selection, 
and to maximize the effectiveness of our predictive procedure 
based on prognostic multi-dimensional EEG profiling. 
    The feature extraction involves various EEG markers whose 
effectiveness was already established in the literature, as 
synchrony measures, complexity-based measures, and non-
linear measures [20-27,34-51].  
    In order to retrieve homogeneous subgroups from the entire 
available population, unsupervised clustering techniques, using 
multi-dimensional feature inputs, are applied. Each obtained 
group will be associated with a given clinical profile.  
    The relationship between the obtained profiles and various 
clinical data (brain amyloid β deposition), socio-demographic 
data (age, education level), and neuropsychological exam scores 
(FCSRT, MMSE, DMS48, Rey figure, DO80, etc) will be 
assessed. This will give us a new insight on the retrieved profile 
characterization of individuals at-risk of AD. 
    For our study, both eyes-closed and eyes-open rsEEG data 
will be used for profiling elderly at-risk for AD, due to the often 
complementary brain processes involved in these two resting 
states. 
    The longitudinal study, at M24 and M30, is a key point for 
this study in order to assess the evolution of the profiles to 
clinical AD and to identify the markers associated to the 
profiles that are at-risk for AD.  
    It is worth noticing that our scientific approach for AD 
prognostic study will be based on our expertise and findings on 
previous databases, especially on Charles-Foix database that 
contains different groups of patients: SCI, MND and AD [21]. 
Concerning EEG markers, we will focus on phase synchrony 
measure, bump modeling, parameters derived from graph 
theory, and Epoch-based Entropy measure that exploits a 
statistical modeling of the quasi-stationary and 
multidimensional EEG signal with Hidden Markov Models.   
 
B. Charles-Foix study 2: AD diagnosis in a differential 
framework 
 
This study was approved by the local ethical committee of Paris 
6. This study will exploit the data collected between 2009 and 
2013 that were analyzed in our previous small-scale study [13], 
and the new EEG data collected at from 2013. 
    In a first step, our methodology proposed in [21] will be 
applied on the new EEG data, in blind manner, to estimate its 
generalization capacity for AD diagnosis. Our proposal in [21] 
exploits two features: entropy-based complexity measure [21-
23] and synchrony measure [71,72], both computed in different 
frequency ranges and for different brain regions. The most 
relevant measures and the most relevant frequency range were 
selected with the Orthogonal Forward Regression (OFR) 
algorithm and the random probe method [73-75] to improve the 
accuracy of EEG classification using a Support Vector Machine 
classifier (SVM) [76,77].      
    Our previous study didn’t focus on MND; this was a 
drawback of our previous published work [21]. Indeed, as 
shown in Table 1, only 60.3% of MCI patients are well 
detected, and among the misclassified MND, 70% of them are 
considered as patients with other pathologies. Thus, we 
propose, in a second step, to apply other EEG markers in order 
to find those that characterize MND group and to evaluate the 
classification accuracy of each group of patients using 
supervised clustering techniques with probabilistic outputs. The 
probabilistic approach is more suitable for decision-making to 
experts. We will evaluate the performance of our proposal in 
terms of specificity and sensitivity. 
    In a third step, instead of assuming a homogeneous behavior 
of each population (SCI, MND, possible AD, and patients with 
other pathologies) like mostly done in the literature, we 
propose to exploit unsupervised clustering techniques, in a 
multimodal framework, on EEG markers to uncover 
homogeneous subgroups from all the population, some of 
which possibly associated with a given cognitive profile. 
 
 
 Table 1: Confusion matrix for AD diagnosis with 4 groups. 
 
 
 
 
 
 
    The relationship between the obtained profiles and various 
clinical data (MMSE, RL/RI-16) will be assessed, which will 
offer an insight on the severity of the cognitive disorder and the 
diagnosis of the disease.  
    Finally, the continuum of the progression towards dementia 
will be studied, by analyzing the evolution of EEG markers and 
clinical data in a transversal way from SCI, MND to AD, 
considering the retrieved cognitive profiles. 
 
VI. EXPECTED IMPACT 
This collaborative research at the regional level may facilitate 
further insight into largely unknown phenomena during the 
progression of AD neuropathology, with a focus on an 
integrative view of the disease, including the extension of new 
knowledge on the cognitive and brain compensation in its early 
stages.  
    Another expected outcome is the development of an 
automatic diagnostic aid-method that will provide a risk 
indicator for AD to the medical doctors at the preclinical stage.   
    Besides, the idea behind this research work is to highlight the 
use of EEG for AD diagnosis. This non-invasive and 
inexpensive technology (20 to 100 times cheaper than a brain 
imaging test) would offer a better patient management by 
allowing low-cost mass screening of AD.  
    This project has also an impact on health and social system. 
In clinical practice, AD is difficult to diagnose and discriminate 
from other pathologies. Misdiagnosed patients suffer from 
unsuitable medical care and have a societal cost. For instance, 
patients suffering from vascular dementia with prior AD 
diagnosis use substantially more medical services every year 
 
Groups SCI AD MND Other 
pathologies 
SCI 81.8% 0% 18.2% 0% 
AD 6.1% 89.9% 2% 2% 
MND 5.2% 6.9% 60.3% 27.6% 
Other 
pathologies 
2.5% 5% 47.5% 45% 
 
until their dementia diagnosis, resulting in incremental annual 
medical costs of approximately $9,500-$14,000 [78].  
    Our proposal of an automatic prediction method to profile 
elderly at-risk for AD and to detect AD at early stage will help 
families and caregivers to undertake the necessary actions 
before the onset of the disease.  
    These preventive actions will allow reducing financial costs 
for healthcare institutions, adapting care programs to each 
individual, and offering a better follow-up and a personalized 
management of patients in hospitals.  
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